30392-40-6 Usage
Uses
Used in Pharmaceutical Industry:
Bitolterol is used as a bronchodilator for the relief of bronchospasm in patients suffering from asthma and chronic obstructive pulmonary disease (COPD). Its ability to stimulate β2-adrenergic receptors in the lungs promotes the relaxation of bronchial muscles and dilation of airways, providing significant relief from respiratory distress.
Brand Name:
Bitolterol is marketed under the brand name Tornalate by Sanofi Aventis, a global pharmaceutical company. This brand name is recognized for its effectiveness in treating respiratory conditions and improving the quality of life for patients with asthma and COPD.
Check Digit Verification of cas no
The CAS Registry Mumber 30392-40-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,0,3,9 and 2 respectively; the second part has 2 digits, 4 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 30392-40:
(7*3)+(6*0)+(5*3)+(4*9)+(3*2)+(2*4)+(1*0)=86
86 % 10 = 6
So 30392-40-6 is a valid CAS Registry Number.
InChI:InChI=1/C28H31NO5/c1-18-6-10-20(11-7-18)26(31)33-24-15-14-22(23(30)17-29-28(3,4)5)16-25(24)34-27(32)21-12-8-19(2)9-13-21/h6-16,23,29-30H,17H2,1-5H3
30392-40-6Relevant academic research and scientific papers
Combined doses
-
, (2008/06/13)
The present invention discloses a method and a pharmaceutical dry powder combined dose for the prophylaxis or treatment of a respiratory disorder in a mammalian host by inhalation of a metered dry powder combined dose of finely divided dry medication powders. At least one dry powder medicament is selected from a first group of bronchodilating medicaments and at least one dry powder medicament from a second group of anti-inflammatory medicaments. A metered dry powder medicinal combined dose comprising separately metered deposits of medicinally suitable quantities of each of the selected medicaments is prepared, in which the sum of the metered deposits constitutes the metered quantities of powder of the combined dose and the medicinal combined dose is introduced into an adapted inhaler device for a generally simultaneous delivery of the medicinal combined dose during the course of a single inhalation by a user, such that the delivered medicinal combined dose is composed of a high proportion of mixed de-aggregated fine particles of the selected medicaments, whereby an desired therapeutic or treating effect to the user is achieved.
